Yu Chen

List of Publications by Year
in descending order

66 papers	18,357 citations	81900 39 h-index	98798 67 g-index
76 all docs	76 docs citations	76 times ranked	23869 citing authors

#	Article	IF	Citations
1	Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. Clinical Cancer Research, 2022, 28, 318-326.	7.0	28
2	Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer. Oncogene, 2022, 41, 671-682.	5.9	8
3	Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3. Journal of Nuclear Medicine, 2022, 63, 1401-1407.	5.0	21
4	Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. Journal of Clinical Oncology, 2022, 40, 997-1008.	1.6	13
5	Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2022, 28, 1507-1517.	7.0	3
6	ETS factors in prostate cancer. Cancer Letters, 2022, 530, 181-189.	7.2	15
7	Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. Cell Reports, 2022, 39, 110595.	6.4	25
8	Characterization of stageâ€specific tumor progression in <i>TMPRSS2â€ERG</i> (fusion)â€driven and nonâ€fusionâ€driven prostate cancer in GEM models. Molecular Carcinogenesis, 2022, 61, 717-734.	2.7	4
9	Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Science, 2022, 376, .	12.6	75
10	Delta-like ligand 3â€“targeted radioimmunotherapy for neuroendocrine prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	17
11	PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. Cancer Discovery, 2022, 12, 2120-2139.	9.4	14
12	Combined Inhibition of GÎ±q and MEK Enhances Therapeutic Efficacy in Uveal Melanoma. Clinical Cancer Research, 2021, 27, 1476-1490.	7.0	29
13	Direct evidence that the GPCR CysLTR2 mutant causative of uveal melanoma is constitutively active with highly biased signaling. Journal of Biological Chemistry, 2021, 296, 100163.	3.4	22
14	Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment. Cancer Research, 2021, 81, 371-383.	0.9	10
15	Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide. Nature Communications, 2021, 12, 866.	12.8	73
16	An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence. Cancer Cell, 2021, 39, 240-256.e11.	16.8	143
17	Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers. Nature Communications, 2021, 12, 5053.	12.8	14
18	Significance of <i>BRCA2</i> and <i>RB1</i> Co-loss in Aggressive Prostate Cancer Progression. Clinical Cancer Research, 2020, 26, 2047-2064.	7.0	77

#	Article	IF	Citations
19	Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2020, 4, 1167-1179.	3.0	28
20	Single-cell transcriptomics identifies a distinct luminal progenitor cell type in distal prostate invagination tips. Nature Genetics, 2020, 52, 908-918.	21.4	77
21	Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity. Nature Communications, 2020, 11, 5549.	12.8	76
22	Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. Nature, 2020, 582, 557-560.	27.8	1,517
23	Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2. Cancer Research, 2020, 80, 1428-1437.	0.9	8
24	Modulation of androgen receptor DNA binding activity through direct interaction with the ETS transcription factor ERG. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 8584-8592.	7.1	35
25	ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming. Journal of Clinical Investigation, 2020, 130, 5924-5941.	8.2	29
26	The androgen receptor regulates a druggable translational regulon in advanced prostate cancer. Science Translational Medicine, 2019, 11, .	12.4	47
27	Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes. Molecular Cancer Therapeutics, 2019, 18, 1577-1586.	4.1	13
28	The novel BETâ€•CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wildâ€•type prostate cancer. EMBO Molecular Medicine, 2019, 11, e10659.	6.9	56
29	PARP Inhibition Suppresses GRâ€“MYCNâ€“CDK5â€“RB1â€“E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 6839-6851.	7.0	50
30	CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. Cancer Cell, 2019, 35, 603-617.e8.	16.8	70
31	GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma. Cell Reports, 2018, 22, 2455-2468.	6.4	75
32	Dual inhibition of <scp>AKT</scp> â€•m <scp>TOR</scp> and <scp>AR</scp> signaling by targeting <scp>HDAC</scp> 3 in <i> <scp>PTEN</scp> </i> â€•or <i> <scp>SPOP</scp> </i> â€•mutated prostate cancer. EMBO Molecular Medicine, 2018, 10, .	6.9	39
33	FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor. Cancer Discovery, 2018, 8, 234-251.	9.4	49
34	COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. Journal of Clinical Investigation, 2018, 128, 1442-1457.	8.2	30
35	<i>TMPRSS2-ERG</i> Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in <i>PTEN</i> and <i>TP53</i>-Mutated Prostate Cancer. Clinical Cancer Research, 2018, 24, 4551-4565.	7.0	51
36	Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers. Journal of Hematology and Oncology, 2018, 11, 78.	17.0	39

#	Article	IF	Citations
37	Patient derived organoids to model rare prostate cancer phenotypes. Nature Communications, 2018, 9, 2404.	12.8	246
38	Stromal Hedgehog signaling maintains smooth muscle and hampers micro-invasive prostate cancer. DMM Disease Models and Mechanisms, 2017, 10, 39-52.	2.4	23
39	The potential of organoids in urological cancer research. Nature Reviews Urology, 2017, 14, 401-414.	3.8	72
40	ETV1-Positive Cells Give Rise to <i>BRAFV600E</i>-Mutant Gastrointestinal Stromal Tumors. Cancer Research, 2017, 77, 3758-3765.	0.9	12
41	SPOP Mutation Drives Prostate Tumorigenesis InÂVivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. Cancer Cell, 2017, 31, 436-451.	16.8	152
42	Prostate cancerâ€“associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nature Medicine, 2017, 23, 1063-1071.	30.7	240
43	Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. Cancer Cell, 2017, 32, 792-806.e7.	16.8	61
44	Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature, 2017, 547, 453-457.	27.8	1,194
45	A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and Colon. PLoS ONE, 2016, 11, e0161084.	2.5	18
46	Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nature Genetics, 2016, 48, 675-680.	21.4	236
47	N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell, 2016, 30, 563-577.	16.8	394
48	Organoid culture systems for prostate epithelial and cancer tissue. Nature Protocols, 2016, 11, 347-358.	12.0	487
49	Analogs of the novel phytohormone, strigolactone, trigger apoptosis and synergize with PARP inhibitors by inducing DNA damage and inhibiting DNA repair. Oncotarget, 2016, 7, 13984-14001.	1.8	30
50	Integrative Clinical Genomics of Advanced Prostate Cancer. Cell, 2015, 161, 1215-1228.	28.9	2,660
51	Prostate cancer organoids: a potential new tool for testing drug sensitivity. Expert Review of Anticancer Therapy, 2015, 15, 261-263.	2.4	47
52	Combined Inhibition of MAP Kinase and KIT Signaling Synergistically Destabilizes ETV1 and Suppresses GIST Tumor Growth. Cancer Discovery, 2015, 5, 304-315.	9.4	102
53	Identifying Actionable Targets through Integrative Analyses of GEM Model and Human Prostate Cancer Genomic Profiling. Molecular Cancer Therapeutics, 2015, 14, 278-288.	4.1	29
54	Organoid development in cancer genome discovery. Current Opinion in Genetics and Development, 2015, 30, 42-48.	3.3	58

#	Article	IF	Citations
55	The Molecular Taxonomy of Primary Prostate Cancer. Cell, 2015, 163, 1011-1025.	28.9	2,435
56	Identification of Multipotent Luminal Progenitor Cells in Human Prostate Organoid Cultures. Cell, 2014, 159, 163-175.	28.9	609
57	Organoid Cultures Derived from Patients with Advanced Prostate Cancer. Cell, 2014, 159, 176-187.	28.9	1,184
58	ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nature Medicine, 2013, 19, 1023-1029.	30.7	251
59	Overcoming mutation-based resistance to antiandrogens with rational drug design. ELife, 2013, 2, e00499.	6.0	334
60	Î²4 Integrin signaling induces expansion of prostate tumor progenitors. Journal of Clinical Investigation, 2013, 123, 682-99.	8.2	74
61	Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer. Cancer Cell, 2011, 19, 575-586.	16.8	1,026
62	ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature, 2010, 467, 849-853.	27.8	279
63	Histone Deacetylases Are Required for Androgen Receptor Function in Hormone-Sensitive and Castrate-Resistant Prostate Cancer. Cancer Research, 2009, 69, 958-966.	0.9	167
64	Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer. Science, 2009, 324, 787-790.	12.6	1,955
65	Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncology, The, 2009, 10, 981-991.	10.7	282
66	Targeting the androgen receptor pathway in prostate cancer. Current Opinion in Pharmacology, 2008, 8, 440-448.	3.5	371